d 3263  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs d 3263
    Cooperative effect of the Trpm8 agonist <t>D−3263</t> with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    D 3263, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d 3263/product/Alomone Labs
    Average 94 stars, based on 7 article reviews
    Price from $9.99 to $1999.99
    d 3263 - by Bioz Stars, 2022-12
    94/100 stars

    Images

    1) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    2) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    3) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    4) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    5) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    6) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    7) Product Images from "Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies"

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    Journal: Biomolecules

    doi: 10.3390/biom12020193

    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    Figure Legend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Techniques Used: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs d 3263
    Cooperative effect of the Trpm8 agonist <t>D−3263</t> with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.
    D 3263, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d 3263/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    d 3263 - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    Image Search Results


    Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Journal: Biomolecules

    Article Title: Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies

    doi: 10.3390/biom12020193

    Figure Lengend Snippet: Cooperative effect of the Trpm8 agonist D−3263 with Enzalutamide or Docetaxel in TRAMP PCa cell lines. ( A , B ) End−point PCR ( A ) and Western blotting ( B ) analyses showing the expression of Trpm8 in TRAMP C1 and C2 cell lines compared to normal mouse prostate AP, DLP and VP lobes. Gapdh was used as loading control. Experiments were performed in quadruplicate. ( C ) Western blotting analysis showing molecular signature of apoptotic cell death (Caspase−3 and Parp cleavage). TRAMP C1 and TRAMP C2 cells were treated with D−3263 (1 μM), Docetaxel (5 nM), Enzalutamide (1 μM), D-3263 + Docetaxel, or D-3263 + Enzalutamide for 24 or 72 h. Untreated cells were used as control. Gapdh was used as loading control. Experiments were performed in triplicates. * Protein extracts from cells treated with Staurosporine (1 μM, 6 h) were used as positive control.

    Article Snippet: A combination of D-3263 with either docetaxel or enzalutamide promotes a mild but consistent cleavage of Caspase 3 in TRAMP-C1 and TRAMP-C2 mouse PCa cell lines at 24 h ( B), while inducing a massive apoptotic response in both TRAMP-C1 and TRAMP-C2 cell lines at 72 h ( C).

    Techniques: Polymerase Chain Reaction, Western Blot, Expressing, Positive Control